What is the importance of anti-TNF agents in the treatment of luminal (inflammatory type) Crohn's disease?

References (12)

1. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn-s disease. Gut 1994; 35: 360-2
2. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255'60
3. Travis SP, Stange EF, M Lémann M, et al., for the European Crohn's and Colitis Organisation (ECCO). European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006; 55 (Suppl 1): i16 - i35
4. Sandborn W, Rutgeerts P, Reinisch W, et al. One year data from the SONIC Study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. DDW, 2009
5. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I Trial. Gastroenterology 2006; 130: 323-33
6. Targan SR, Hanauer SB, van Deventer SJ, et al., for the Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997; 337: 1029-35
7. Schröder O, Blumenstein I, Stein J. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn-s disease: a controlled pilot study. Eur J Gastroenterol Hepatol 2006; 18: 11-6
8. D-Haens G, Baert F, van Assche G, et al., for the Belgian Inflammatory Bowel Disease Research Group and the North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-7
9. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab. A randomized trial. Ann Intern Med 2007; 146: 829-38
10. Sandborn WJ, Feagan BG, Hanauer SB, et al., for the CDP571 Crohn-s D-sease Study Group. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001; 120: 1330-8
11. Baert FJ, D-haens GR, Peeters M, et al. Tumor necrosis factor a antibody (Infliximab) therapy profoundly down-regulates the inflammation in Crohn-s ileocolitis. Gastroenterology 1999; 116: 22-8
12. Van Assche G, Magdelaine-Beuzelin C, D-haens G, et al. Withdrawal